Title: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Journal: Drugs 20170701
Title: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.
Journal: Canadian journal of gastroenterology & hepatology 20150101
Title: A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity.
Journal: Nature chemical biology 20140801
Title: The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Journal: Antimicrobial agents and chemotherapy 20140601
Title: Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
Journal: Journal of medicinal chemistry 20140313
Title: Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
Journal: Hepatology (Baltimore, Md.) 20140201
Title: Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20131201
Title: In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Journal: Antiviral research 20131101
Title: Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.
Journal: Antimicrobial agents and chemotherapy 20130901
Title: Primuline derivatives that mimic RNA to stimulate hepatitis C virus NS3 helicase-catalyzed ATP hydrolysis.
Journal: The Journal of biological chemistry 20130705
Title: Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity.
Journal: Bioorganic & medicinal chemistry 20130515
Title: Direct-acting antiviral agents for hepatitis C virus infection.
Journal: Annual review of pharmacology and toxicology 20130101
Title: Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
Journal: Hepatology (Baltimore, Md.) 20121101
Title: Boceprevir: a protease inhibitor for the treatment of hepatitis C.
Journal: Clinical therapeutics 20121001
Title: Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.
Journal: Hepatology (Baltimore, Md.) 20120901
Title: HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120901
Title: Factors that predict response of patients with hepatitis C virus infection to boceprevir.
Journal: Gastroenterology 20120901
Title: Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.
Journal: The Lancet. Infectious diseases 20120901
Title: Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Journal: Clinical pharmacokinetics 20120901
Title: New pharmacotherapy for hepatitis C.
Journal: Clinical pharmacology and therapeutics 20120901
Title: Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
Journal: Hepatology (Baltimore, Md.) 20120801
Title: Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers.
Journal: Southern medical journal 20120801
Title: HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120715
Title: Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?
Journal: Hepatology (Baltimore, Md.) 20120701
Title: Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120701
Title: Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.
Journal: Current opinion in organ transplantation 20120601
Title: Hepatitis drug reduces effects of HIV medications.
Journal: JAMA 20120523
Title: New genetic discoveries and treatment for hepatitis C.
Journal: JAMA 20120509
Title: Review and management of drug interactions with boceprevir and telaprevir.
Journal: Hepatology (Baltimore, Md.) 20120501
Title: [Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].
Journal: Gastroenterologia y hepatologia 20120501
Title: Hepatitis C and substance use: new treatments and novel approaches.
Journal: Current opinion in psychiatry 20120501
Title: A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
Journal: Journal of viral hepatitis 20120501
Title: Hepatitis C therapy update.
Journal: Current opinion in gastroenterology 20120501
Title: New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
Journal: Gut 20120501
Title: Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
Journal: Trends in pharmacological sciences 20120501
Title: Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.
Journal: The American journal of gastroenterology 20120501
Title: New virologic tools for management of chronic hepatitis B and C.
Journal: Gastroenterology 20120501
Title: Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Journal: Gastroenterology 20120501
Title: Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Journal: Gastroenterology 20120501
Title: Genetic factors and hepatitis C virus infection.
Journal: Gastroenterology 20120501
Title: Targeted therapies for hepatitis C reach the clinic.
Journal: Chemistry & biology 20120420
Title: Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
Journal: Journal of medicinal chemistry 20120412
Title: Efficient, chemoenzymatic process for manufacture of the Boceprevir bicyclic [3.1.0]proline intermediate based on amine oxidase-catalyzed desymmetrization.
Journal: Journal of the American Chemical Society 20120411
Title: Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.
Journal: Hepatology (Baltimore, Md.) 20120401
Title: Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120401
Title: [Current indications for triple therapy in hepatitis C virus infection].
Journal: Gastroenterologia y hepatologia 20120401
Title: Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.
Journal: Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20120401
Title: Boceprevir.
Journal: Prescrire international 20120401
Title: [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Journal: Orvosi hetilap 20120311
Title: Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
Journal: Gastroenterology 20120301
Title: UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Journal: Alimentary pharmacology & therapeutics 20120301
Title: New drugs 2012 part I.
Journal: Nursing 20120301
Title: Protease inhibitors: silver bullets for chronic hepatitis C infection?
Journal: Cleveland Clinic journal of medicine 20120301
Title: Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
Journal: Expert review of anti-infective therapy 20120301
Title: Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Journal: Minerva gastroenterologica e dietologica 20120301
Title: Annual drug update: 2011 in review.
Journal: The Nurse practitioner 20120212
Title: The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice.
Journal: Journal of hepatology 20120201
Title: Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.
Journal: Current gastroenterology reports 20120201
Title: Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Future treatment of patients with HCV cirrhosis.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Hepatitis C virus treatment pre- and post-liver transplantation.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Hepatitis C virus-human immunodeficiency virus coinfection.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: What's new in HCV genotype 2 treatment.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: The future for the treatment of genotype 4 chronic hepatitis C.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Barriers to hepatitis C treatment.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b.
Journal: Journal of viral hepatitis 20120201
Title: Treatment failure with new hepatitis C drugs.
Journal: Expert opinion on pharmacotherapy 20120201
Title: Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
Journal: Pharmacotherapy 20120201
Title: Triple therapy for hepatitis C.
Journal: JAAPA : official journal of the American Academy of Physician Assistants 20120201
Title: Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120101
Title: [Boceprevir-benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dosage evaluation)].
Journal: Zeitschrift fur Gastroenterologie 20120101
Title: [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].
Journal: Zeitschrift fur Gastroenterologie 20120101
Title: New developments in HCV therapy.
Journal: Journal of viral hepatitis 20120101
Title: Boceprevir, telaprevir, and rilpivirine hydrochloride.
Journal: Journal of the American Pharmacists Association : JAPhA 20120101
Title: [Victrelis and Incivek against hepatitis C: some promising options].
Journal: Perspective infirmiere : revue officielle de l'Ordre des infirmieres et infirmiers du Quebec 20120101
Title: Antiviral strategies in hepatitis C virus infection.
Journal: Journal of hepatology 20120101
Title: A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.
Journal: Annals of hepatology 20120101
Title: Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
Journal: Swiss medical weekly 20120101
Title: Advances in the treatment of hepatitis C virus infection.
Journal: Topics in antiviral medicine 20120101
Title: [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
Journal: Przeglad epidemiologiczny 20120101
Title: Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy.
Journal: Nature reviews. Gastroenterology & hepatology 20111220
Title: [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Journal: Orvosi hetilap 20111211
Title: New HCV drugs trigger race for more tolerable therapies.
Journal: Nature medicine 20111206
Title: Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20111201
Title: Boceprevir.
Journal: Hepatology (Baltimore, Md.) 20111201
Title: Telaprevir for the treatment of chronic hepatitis C infection.
Journal: Expert review of anti-infective therapy 20111201
Title: A major advance in treating hepatitis C.
Journal: The Johns Hopkins medical letter health after 50 20111201
Title: Direct-acting antiviral (DAA) actions in treatment-naïve patients.
Journal: Clinics and research in hepatology and gastroenterology 20111201
Title: Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients.
Journal: Clinics and research in hepatology and gastroenterology 20111201
Title: New hepatitis C regimen stimulates changes in therapy management.
Journal: Managed care (Langhorne, Pa.) 20111201
Title: Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
Journal: AIDS (London, England) 20111128
Title: Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.
Journal: BMJ (Clinical research ed.) 20111110
Title: New treatments for chronic hepatitis C virus infection.
Journal: Medecine et maladies infectieuses 20111101
Title: Future of hepatitis C therapy: development of direct-acting antivirals.
Journal: Current opinion in HIV and AIDS 20111101
Title: Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Journal: Current opinion in HIV and AIDS 20111101
Title: Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
Journal: Journal of managed care pharmacy : JMCP 20111101
Title: The expanding role of the pharmacist in the management of hepatitis C infection.
Journal: Journal of managed care pharmacy : JMCP 20111101
Title: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
Journal: Hepatology (Baltimore, Md.) 20111001
Title: Antiviral drugs for viruses other than human immunodeficiency virus.
Journal: Mayo Clinic proceedings 20111001
Title: Boceprevir.
Journal: Drugs of today (Barcelona, Spain : 1998) 20111001
Title: [New triple therapy in chronic hepatitis C. Increased patient chances].
Journal: MMW Fortschritte der Medizin 20110929
Title: [New treatments for hepatitis C, which targets, what timeline?].
Journal: Revue medicale suisse 20110907
Title: Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
Journal: Gastroenterology 20110901
Title: Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
Journal: The Annals of pharmacotherapy 20110901
Title: Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals.
Journal: Gastroenterology clinics of North America 20110901
Title: Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
Journal: Expert review of anti-infective therapy 20110901
Title: Protease inhibitors in hepatitis C: from chronic disease to cure.
Journal: Irish medical journal 20110901
Title: Directly acting antivirals against hepatitis C virus.
Journal: The Journal of antimicrobial chemotherapy 20110801
Title: HCV protease inhibitors bring new options for patients.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110801
Title: Going viral.
Journal: Scientific American 20110801
Title: An overview of emerging therapies for the treatment of chronic hepatitis C.
Journal: Clinics in liver disease 20110801
Title: Boceprevir: a user's guide.
Journal: Clinics in liver disease 20110801
Title: Second-wave protease inhibitors: choosing an heir.
Journal: Clinics in liver disease 20110801
Title: Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C.
Journal: The Medical letter on drugs and therapeutics 20110725
Title: [Studies with boceprevir].
Journal: MMW Fortschritte der Medizin 20110721
Title: [A new era in therapy of hepatitis C: 'the therapy can now be individualized' (interview by Dr. med. Dirk Einecke)].
Journal: MMW Fortschritte der Medizin 20110721
Title: Boceprevir for chronic HCV genotype 1 infection.
Journal: The New England journal of medicine 20110714
Title: Boceprevir for chronic HCV genotype 1 infection.
Journal: The New England journal of medicine 20110714
Title: New Merck and Vertex drugs raise standard of care in hepatitis C.
Journal: Nature biotechnology 20110711
Title: Hepatitis C virus resistance to protease inhibitors.
Journal: Journal of hepatology 20110701
Title: Two drugs approved for chronic hepatitis C infection.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110701
Title: Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail.
Journal: Hepatology (Baltimore, Md.) 20110701
Title: Introduction: a smouldering public-health crisis.
Journal: Nature 20110608
Title: Therapeutics: new drugs hit the target.
Journal: Nature 20110608
Title: Perspective: miles to go before we sleep.
Journal: Nature 20110608
Title: Distributive justice and the arrival of direct-acting antivirals: who should be first in line?
Journal: Hepatology (Baltimore, Md.) 20110601
Title: FDA Advisory Committee reviews safety of boceprevir.
Journal: AIDS patient care and STDs 20110601
Title: [New therapeutic options in chronic hepatitis C virus infection].
Journal: Orvosi hetilap 20110529
Title: Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
Journal: Journal of viral hepatitis 20110501
Title: A new standard of care for the treatment of chronic HCV infection.
Journal: Nature reviews. Gastroenterology & hepatology 20110501
Title: Viral hepatitis: progress and promise.
Journal: Nature reviews. Gastroenterology & hepatology 20110501
Title: Infectious diseases. First specific drugs raise hopes for hepatitis C.
Journal: Science (New York, N.Y.) 20110408
Title: Boceprevir for untreated chronic HCV genotype 1 infection.
Journal: The New England journal of medicine 20110331
Title: Boceprevir for previously treated chronic HCV genotype 1 infection.
Journal: The New England journal of medicine 20110331
Title: A new era of hepatitis C therapy begins.
Journal: The New England journal of medicine 20110331
Title: Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110301
Title: The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.
Journal: Gastroenterology 20110301
Title: Drugs in development for viral hepatitis: care and caution.
Journal: Drugs 20110212
Title: Big changes are coming in hepatitis C.
Journal: Current gastroenterology reports 20110201
Title: Hepatitis in 2010: the dawn of a new era in HCV therapy.
Journal: Nature reviews. Gastroenterology & hepatology 20110201
Title: [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].
Journal: Pharmazie in unserer Zeit 20110101
Title: The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20110101
Title: The role of triple therapy in HCV genotype 1-experienced patients.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20110101
Title: New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20110101
Title: Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Journal: Antiviral therapy 20110101
Title: New therapies for hepatitis C virus infection.
Journal: Missouri medicine 20110101
Title: Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Journal: Antiviral therapy 20110101
Title: Hepatitis C therapy in 2011: is less more, is more less?
Journal: The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20110101
Title: IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.
Journal: Romanian journal of internal medicine = Revue roumaine de medecine interne 20110101
Title: Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
Journal: Antimicrobial agents and chemotherapy 20101201
Title: Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.
Journal: Viruses 20101201
Title: Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
Journal: Antimicrobial agents and chemotherapy 20101101
Title: Boceprevir.
Journal: Drugs in R&D 20100901
Title: STAT-C: a full revolution or just a step forward?
Journal: Lancet (London, England) 20100828
Title: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Journal: Lancet (London, England) 20100828
Title: Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel.
Journal: Viruses 20100801
Title: Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
Journal: Bioorganic & medicinal chemistry 20100715
Title: The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors.
Journal: The Journal of infectious diseases 20100701
Title: Excitement grows for potential revolution in hepatitis C virus treatment.
Journal: Nature reviews. Drug discovery 20100701
Title: Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
Journal: Antimicrobial agents and chemotherapy 20100601
Title: New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
Journal: The Journal of antimicrobial chemotherapy 20100601
Title: In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
Journal: Antimicrobial agents and chemotherapy 20100501
Title: Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
Journal: Journal of medicinal chemistry 20100422
Title: The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.
Journal: Bioorganic & medicinal chemistry letters 20100415
Title: Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
Journal: Bioorganic & medicinal chemistry letters 20100401
Title: Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20100301
Title: Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
Journal: Bioorganic & medicinal chemistry 20100301
Title: Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
Journal: International journal of antimicrobial agents 20100201
Title: P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
Journal: Bioorganic & medicinal chemistry letters 20100115
Title: MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
Journal: Antimicrobial agents and chemotherapy 20100101
Title: Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease.
Journal: Current topics in medicinal chemistry 20100101
Title: On the cusp of change: new therapeutic modalities for HCV.
Journal: Annals of hepatology 20100101
Title: Medicinial chemistry. Preface.
Journal: Progress in medicinal chemistry 20100101
Title: The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
Journal: Progress in medicinal chemistry 20100101
Title: Prompt arrival of antivirals against hepatitis C for HIV patients.
Journal: AIDS reviews 20100101
Title: Treatment of hepatitis C in 2011.
Journal: Journal of Ayub Medical College, Abbottabad : JAMC 20100101
Title: Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
Journal: Hepatology (Baltimore, Md.) 20091201
Title: Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091201
Title: A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
Journal: Antiviral research 20091101
Title: [New antiviral agents against hepatitis C in clinical trials. Hope for a cure--but resistance problems must be overcomed].
Journal: Lakartidningen 20091101
Title: HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.
Journal: Biochimica et biophysica acta 20091001
Title: Hepatitis C drug development at a crossroads.
Journal: Hepatology (Baltimore, Md.) 20091001
Title: Potent aza-peptide derived inhibitors of HCV NS3 protease.
Journal: Bioorganic & medicinal chemistry letters 20090815
Title: Boceprevir, an NS3 protease inhibitor of HCV.
Journal: Clinics in liver disease 20090801
Title: Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
Journal: Bioorganic & medicinal chemistry 20090701
Title: Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
Journal: Journal of medicinal chemistry 20090625
Title: Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
Journal: Journal of medicinal chemistry 20090514
Title: Substituted imidazopyridines as potent inhibitors of HCV replication.
Journal: Journal of hepatology 20090501
Title: Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20090415
Title: [Novel treatment for chronic hepatitis C in near future].
Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20090401
Title: Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
Journal: Journal of medicinal chemistry 20090312
Title: Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
Journal: Bioorganic & medicinal chemistry letters 20090215
Title: Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.
Journal: Journal of medicinal chemistry 20090212
Title: Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.
Journal: Current gastroenterology reports 20090201
Title: Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.
Journal: Current opinion in investigational drugs (London, England : 2000) 20090201
Title: Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
Journal: Journal of medicinal chemistry 20090122
Title: Potent inhibitors of HCV-NS3 protease derived from boronic acids.
Journal: Bioorganic & medicinal chemistry letters 20090101
Title: Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
Journal: Antimicrobial agents and chemotherapy 20081201
Title: Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Journal: Hepatology (Baltimore, Md.) 20081201
Title: Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay.
Journal: Journal of virological methods 20081101
Title: Hepatitis C Virus NS3/4A Protease Inhibitors.
Journal: Recent patents on anti-infective drug discovery 20081101
Title: Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034.
Journal: Bioorganic & medicinal chemistry letters 20080715
Title: [The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
Journal: Orvosi hetilap 20080713
Title: Hepatitis C protease and polymerase inhibitors in development.
Journal: AIDS patient care and STDs 20080601
Title: Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034.
Journal: Journal of synchrotron radiation 20080501
Title: Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
Journal: Bioorganic & medicinal chemistry 20080315
Title: Characterization of resistance mutations against HCV ketoamide protease inhibitors.
Journal: Antiviral research 20080301
Title: Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue.
Journal: Bioorganic & medicinal chemistry 20080215
Title: Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.
Journal: Virology 20080120
Title: Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Journal: Accounts of chemical research 20080101
Title: Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
Journal: Antiviral therapy 20080101
Title: Future treatment options for HCV: double, triple, what is the optimal combination?
Journal: Best practice & research. Clinical gastroenterology 20080101
Title: Ultra-performance liquid chromatography/tandem mass spectrometric determination of diastereomers of SCH 503034 in monkey plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601
Title: Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
Journal: Journal of medicinal chemistry 20070517
Title: SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
Journal: Gastroenterology 20070401
Title: Treatment of hepatitis C: don't put all your eggs in one basket!
Journal: Gastroenterology 20070401
Title: Specific targeted antiviral therapy for hepatitis C.
Journal: Current gastroenterology reports 20070301
Title: [Drugs for hepatitis B and C infection].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20070227
Title: Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.
Journal: Antiviral chemistry & chemotherapy 20070101
Title: Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.
Journal: Journal of medicinal chemistry 20061005
Title: Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
Journal: Antiviral research 20060601
Title: SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.
Journal: Antimicrobial agents and chemotherapy 20060301
Title: Njoroge FG, et al. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res. 2008 Jan;41(1):50-9.
Title: Yao M, et al. Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A ProteaseActivity. PLoS One. 2016 Mar 4;11(3):e0150894.
Title: Coilly A, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother. 2012 Nov;56(11):5728-34.
Title: Berenguer M, et al. New developments in the management of hepatitis C virus infection: focus on boceprevir. Biologics. 2012;6:249-56.
Title: Burton MJ, et al. Telaprevir and boceprevir in african americans with genotype 1 chronic hepatitis C: implications for patients and providers. South Med J. 2012 Aug;105(8):431-6.
Title: Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
